68Ga-galectracer PET检测的半乳糖凝集素表达可作为放疗抵抗的预测性生物标志物
本研究合成靶向半乳糖凝集素的放射性示踪剂68Ga-galectracer,在三种小鼠肿瘤缺氧模型中行PET显像,并在两例肺癌患者中行初步PET/CT。结果显示该示踪剂可高对比度检出肿瘤缺氧,在4T1肿瘤中缺氧检测优于18F-米索硝唑;高半乳糖凝集素表达肿瘤对后续放疗反应显著低于低表达者。
要点
- 68Ga-galectracer在三种小鼠缺氧肿瘤模型中均实现高对比度PET显像。
- 在4T1肿瘤中,68Ga-galectracer的缺氧检测优于18F-米索硝唑。
- 高半乳糖凝集素表达肿瘤对后续放疗反应显著低于低表达肿瘤。
核心结论
- 68Ga-galectracer是有前景的体内肿瘤缺氧PET显像示踪剂。
- 68Ga-galectracer缺氧PET可无创性地主动预测放疗疗效。
研究设计与样本
- 合成靶向半乳糖凝集素的放射性示踪剂68Ga-galectracer,由硫代二半乳糖苷衍生物放射性标记而成。
- 在三种小鼠肿瘤缺氧模型中表征68Ga-galectracer的肿瘤缺氧PET显像特性。
- 对两例肺癌患者行初步PET/CT,探讨68Ga-galectracer的临床显像应用潜力。
- 试验注册于Chictr.org.cn(ChiCTR2000029522),注册日期2020年2月3日。
主要发现
- 在小鼠急性缺氧肿瘤模型、A549自然缺氧模型和索拉非尼治疗诱导缺氧的4T1肿瘤模型中,68Ga-galectracer PET均实现高对比度显像。
- 在4T1肿瘤中,68Ga-galectracer的缺氧检测优于18F-米索硝唑。
- 68Ga-galectracer PET检测为高半乳糖凝集素表达的肿瘤,对后续放疗的反应显著低于低表达肿瘤。
- 在肺癌患者中,68Ga-galectracer PET提供的数据与葡萄糖代谢PET示踪剂18F-氟脱氧葡萄糖的数据互补。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Hypoxia is a hallmark of solid tumors that is related to radiotherapy resistance. As galectin members, such as galectin-1 and galectin-3, are associated with tumor hypoxia, herein we aimed to investigate whether positron emission tomography (PET) imaging of galectin expression can be employed to effectively pinpoint tumor hypoxia, and to predict radiotherapy resistance. METHODS: We synthesized a galectin-targeting radiotracer, designated 68Ga-galectracer, by radiolabeling a thiodigalactoside derivative. The properties of 68Ga-galectracer for PET imaging of tumor hypoxia were characterized in three tumor hypoxia mouse models. Additionally, preliminary PET/CT was performed in two patients with lung cancer to investigate the potential application of 68Ga-galectracer for clinical imaging. RESULTS: High-contrast imaging was achieved in the murine acute hypoxia tumor model, A549 natural hypoxia model, and sorafenib treatment-induced hypoxic 4T1 tumor model by PET using 68Ga-galectracer. In fact, 68Ga-galectracer exhibited superior hypoxia detection to that of 18F-misonidazole in the 4T1 tumors. Moreover, tumors with high galectin expression levels, as detected by 68Ga-galectracer PET, exhibited significantly lower responses to subsequent radiotherapy compared to those with low galectin expression levels. In patients with lung cancer, PET imaging using 68Ga-galectracer provided data that were complementary to that of the glucose metabolic PET radiotracer 18F-fluorodeoxyglucose. CONCLUSION: 68Ga-galectracer is a promising radiotracer for PET-based imaging of tumor hypoxia in vivo. Thus, hypoxia PET with 68Ga-galectracer could provide a noninvasive approach to proactively predict radiotherapy efficacy. TRIAL REGISTRATION: Chictr.org.cn (ChiCTR2000029522). Registered 03 February 2020.
引用
- Lu D, Zhou H, Li N, et al. Galectin expression detected by 68Ga-galectracer PET as a predictive biomarker of radiotherapy resistance. Eur J Nucl Med Mol Imaging. 2022. PMID: 35106644. doi:10.1007/s00259-022-05711-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。